Uyanik B, Goloudina A, Akbarali A, Grigorash B, Petukhov A, Singhal S, et al. Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses. Nat Commun. 2021;12:3622 pubmed publisher

Totten S, Im Y, Cepeda Cañedo E, Najyb O, Nguyen A, Hebert S, et al. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nat Commun. 2021;12:3299 pubmed publisher

Lu C, Liu Z, Klement J, Yang D, Merting A, Poschel D, et al. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. J Immunother Cancer. 2021;9: pubmed publisher

Choi Y, Kim Y, Oh S, Suh K, Kim Y, Lee G, et al. Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer. Adv Sci (Weinh). 2021;8:2002497 pubmed publisher

Mpekris F, Panagi M, Voutouri C, Martin J, Samuel R, Takahashi S, et al. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis. Adv Sci (Weinh). 2021;8:2001917 pubmed publisher

Kim H, Kim H, Lee E, Choi B, Jang H, Choi Y. A Quenched Annexin V-Fluorophore for the Real-Time Fluorescence Imaging of Apoptotic Processes In Vitro and In Vivo. Adv Sci (Weinh). 2020;7:2002988 pubmed publisher

Baraibar I, Roman M, Rodriguez Remirez M, Lopez I, Vilalta A, Guruceaga E, et al. Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. Cancers (Basel). 2020;12: pubmed publisher

Zhou T, Damsky W, Weizman O, McGeary M, Hartmann K, Rosen C, et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature. 2020;583:609-614 pubmed publisher

Waaler J, Mygland L, Tveita A, Strand M, Solberg N, Olsen P, et al. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models. Commun Biol. 2020;3:196 pubmed publisher

Santana Magal N, Farhat Younis L, Gutwillig A, Gleiberman A, Rasoulouniriana D, Tal L, et al. Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy. Cancer Res. 2020;80:1942-1956 pubmed publisher

Li Y, Zhang M, Wang X, Liu W, Wang H, Yang Y. Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice. Nat Commun. 2020;11:581 pubmed publisher

Sun G, Cao Y, Qian C, Wan Z, Zhu J, Guo J, et al. Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages. Aging (Albany NY). 2020;12:1114-1127 pubmed publisher

Zhong W, Myers J, Wang F, Wang K, Lucas J, Rosfjord E, et al. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics. 2020;21:2 pubmed publisher

Krotova K, Day A, Aslanidi G. An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation. Mol Ther Oncolytics. 2019;15:166-177 pubmed publisher

Panigrahy D, Gartung A, Yang J, Yang H, Gilligan M, Sulciner M, et al. Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. J Clin Invest. 2019;129:2964-2979 pubmed publisher

Konen J, Rodriguez B, Fradette J, Gibson L, Davis D, Minelli R, et al. Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers (Basel). 2019;11: pubmed publisher

Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher

Liao W, Overman M, Boutin A, Shang X, Zhao D, Dey P, et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019;35:559-572.e7 pubmed publisher

Blair A, Kleponis J, Thomas D, Muth S, Murphy A, Kim V, et al. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. J Clin Invest. 2019;129:1742-1755 pubmed publisher

Shields B, Koss B, Taylor E, Storey A, West K, Byrum S, et al. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Res. 2019;79:1113-1123 pubmed publisher

Liu C, He H, Li X, Su M, Cao Y. Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. Br J Cancer. 2019;120:346-355 pubmed publisher

Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin G, Shurin M, et al. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc Natl Acad Sci U S A. 2019;116:1361-1369 pubmed publisher

Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, et al. Induction of immunosuppressive functions and NF-κB by FLIP in monocytes. Nat Commun. 2018;9:5193 pubmed publisher

Sato Y, Bolzenius J, Eteleeb A, Su X, Maher C, Sehn J, et al. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight. 2018;3: pubmed publisher

Andre P, Denis C, Soulas C, Bourbon Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175:1731-1743.e13 pubmed publisher

van Montfoort N, Borst L, Korrer M, Sluijter M, Marijt K, Santegoets S, et al. NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines. Cell. 2018;175:1744-1755.e15 pubmed publisher

Sato Kaneko F, Wang X, Yao S, Hosoya T, Lao F, Messer K, et al. Discovery of a Novel Microtubule Targeting Agent as an Adjuvant for Cancer Immunotherapy. Biomed Res Int. 2018;2018:8091283 pubmed publisher

Grasselly C, Denis M, Bourguignon A, Talhi N, Mathé D, Tourette A, et al. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Front Immunol. 2018;9:2100 pubmed publisher

Vuckovic S, Minnie S, Smith D, Gartlan K, Watkins T, Markey K, et al. Bone marrow transplantation generates T cell-dependent control of myeloma in mice. J Clin Invest. 2019;129:106-121 pubmed publisher

Leung C, Yang K, Li X, Chan V, Ku M, Waldmann H, et al. Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells. Genome Med. 2018;10:71 pubmed publisher

Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018;128:5137-5149 pubmed publisher

Dorta Estremera S, Chin R, Sierra G, Nicholas C, Yanamandra A, Nookala S, et al. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers. Cancer Res. 2018;78:5327-5339 pubmed publisher

Ghaffari A, Peterson N, Khalaj K, Vitkin N, Robinson A, Francis J, et al. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br J Cancer. 2018;119:440-449 pubmed publisher

Triplett T, Garrison K, Marshall N, Donkor M, Blazeck J, Lamb C, et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat Biotechnol. 2018;36:758-764 pubmed publisher

Choi J, Beaino W, Fecek R, Fabian K, Laymon C, Kurland B, et al. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. J Nucl Med. 2018;59:1843-1849 pubmed publisher

Li J, Byrne K, Yan F, Yamazoe T, Chen Z, Baslan T, et al. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity. 2018;49:178-193.e7 pubmed publisher

Zhu B, Tang L, Chen S, Yin C, Peng S, Li X, et al. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene. 2018;37:4941-4954 pubmed publisher

Li X, Das I, Lepletier A, Addala V, Bald T, Stannard K, et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest. 2018;128:2613-2625 pubmed publisher

Crosby E, Wei J, Yang X, Lei G, Wang T, Liu C, et al. Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology. 2018;7:e1421891 pubmed publisher

Anker J, Naseem A, Mok H, Schaeffer A, Abdulkadir S, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun. 2018;9:1591 pubmed publisher

Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari Mimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. 2018;115:E4041-E4050 pubmed publisher

Bohineust A, Garcia Z, Beuneu H, Lemaitre F, Bousso P. Termination of T cell priming relies on a phase of unresponsiveness promoting disengagement from APCs and T cell division. J Exp Med. 2018;215:1481-1492 pubmed publisher

Tamosiuniene R, Manouvakhova O, Mésange P, Saito T, Qian J, Sanyal M, et al. Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension. Circ Res. 2018;122:1689-1702 pubmed publisher

Xi J, Huang Q, Wang L, Ma X, Deng Q, Kumar M, et al. miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. Oncogene. 2018;37:3151-3165 pubmed publisher

Zamarin D, Ricca J, Sadekova S, Oseledchyk A, Yu Y, Blumenschein W, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128:1413-1428 pubmed publisher

Taggart D, Andreou T, Scott K, Williams J, Rippaus N, Brownlie R, et al. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking. Proc Natl Acad Sci U S A. 2018;115:E1540-E1549 pubmed publisher

Tang H, Liang Y, Anders R, Taube J, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018;128:580-588 pubmed publisher

Tavazoie M, Pollack I, Tanqueco R, Ostendorf B, Reis B, Gonsalves F, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018;172:825-840.e18 pubmed publisher

Roussey J, Viglianti S, Teitz Tennenbaum S, Olszewski M, Osterholzer J. Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice. J Immunol. 2017;199:3535-3546 pubmed publisher

Huffaker T, Lee S, Tang W, Wallace J, Alexander M, Runtsch M, et al. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. J Biol Chem. 2017;292:18530-18541 pubmed publisher

Grinberg Bleyer Y, Oh H, Desrichard A, Bhatt D, Caron R, Chan T, et al. NF-?B c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. Cell. 2017;170:1096-1108.e13 pubmed publisher

Bucsek M, Qiao G, MacDonald C, Giridharan T, Evans L, Niedzwecki B, et al. β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy. Cancer Res. 2017;77:5639-5651 pubmed publisher

Trsan T, Vuković K, Filipović P, Brizić A, Lemmermann N, Schober K, et al. Cytomegalovirus vector expressing RAE-1? induces enhanced anti-tumor capacity of murine CD8+ T cells. Eur J Immunol. 2017;47:1354-1367 pubmed publisher

Kwan B, Zhu E, Tzeng A, Sugito H, Eltahir A, Ma B, et al. Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. J Exp Med. 2017;214:1679-1690 pubmed publisher

Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250-254 pubmed publisher

Bartee M, Dunlap K, Bartee E. Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Res. 2017;77:2952-2963 pubmed publisher

Beavis P, Henderson M, Giuffrida L, Mills J, Sek K, Cross R, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127:929-941 pubmed publisher

Spitzer M, Carmi Y, Reticker Flynn N, Kwek S, Madhireddy D, Martins M, et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell. 2017;168:487-502.e15 pubmed publisher

Moynihan K, Opel C, Szeto G, Tzeng A, Zhu E, Engreitz J, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22:1402-1410 pubmed publisher

Zelenay S, van der Veen A, Böttcher J, Snelgrove K, Rogers N, Acton S, et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. 2015;162:1257-70 pubmed publisher

Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher

Zander R, Obeng Adjei N, Guthmiller J, Kulu D, Li J, Ongoiba A, et al. PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host Microbe. 2015;17:628-41 pubmed publisher

Vanpouille Box C, Diamond J, Pilones K, Zavadil J, Babb J, Formenti S, et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 2015;75:2232-42 pubmed publisher

Twyman Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-7 pubmed publisher

Prendergast C, Sanin D, Cook P, Mountford A. CD4+ T cell hyporesponsiveness after repeated exposure to Schistosoma mansoni larvae is dependent upon interleukin-10. Infect Immun. 2015;83:1418-30 pubmed publisher

Evans E, Jonason A, Bussler H, Torno S, Veeraraghavan J, Reilly C, et al. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunol Res. 2015;3:689-701 pubmed publisher

Mittal D, Young A, Stannard K, Yong M, Teng M, Allard B, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014;74:3652-8 pubmed publisher

McGray A, Hallett R, Bernard D, Swift S, Zhu Z, Teoderascu F, et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther. 2014;22:206-18 pubmed publisher

John L, Devaud C, Duong C, Yong C, Beavis P, Haynes N, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636-46 pubmed publisher

Holmgaard R, Zamarin D, Munn D, Wolchok J, Allison J. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210:1389-402 pubmed publisher

Van Der Werf N, Redpath S, Azuma M, Yagita H, Taylor M. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog. 2013;9:e1003215 pubmed publisher

Curran M, Montalvo W, Yagita H, Allison J. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275-80 pubmed publisher